Polatuzumab vedotin targets CD79b on B cells; after internalization it releases MMAE, which binds beta-tubulin and blocks microtubule polymerization, causing G2/M arrest and apoptosis in CD79b+ cells. Tubulin expression alone is not sufficient for targeting or killing.